1
|
Karaman B, Battal B, Sari S and Verim S:
Hepatocellular carcinoma review: Current treatment, and
evidence-based medicine. World J Gastroenterol. 20:18059–18060.
2014.PubMed/NCBI
|
2
|
Olsen SK, Brown RS and Siegel AB:
Hepatocellular carcinoma: Review of current treatment with a focus
on targeted molecular therapies. Therap Adv Gastroenterol. 3:55–66.
2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hong TS: Radiotherapy for hepatocellular
carcinoma with tumor vascular thrombus: Ready for prime time? J
Clin Oncol. 31:1619–1620. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Singh S, Singh PP, Roberts LR and Sanchez
W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol. 11:45–54. 2014. View Article : Google Scholar
|
5
|
Klein J and Dawson LA: Hepatocellular
carcinoma radiation therapy: Review of evidence and future
opportunities. Int J Radiat Oncol Biol Phys. 87:22–32. 2013.
View Article : Google Scholar
|
6
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bouyssou JM, Manier S, Huynh D, Issa S,
Roccaro AM and Ghobrial IM: Regulation of microRNAs in cancer
metastasis. Biochim Biophys Acta. 1845:255–265. 2014.PubMed/NCBI
|
10
|
Dumortier O, Hinault C and Van Obberghen
E: MicroRNAs and metabolism crosstalk in energy homeostasis. Cell
Metab. 18:312–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Misso G, Di Martino MT, De Rosa G, Farooqi
AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P,
Tassone P and Caraglia M: Mir-34: A new weapon against cancer? Mol
Ther Nucleic Acids. 3:e1942014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Chang TC, Wentzel EA, Kent OA,
Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M,
Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53
broadly influences gene expression and promotes apoptosis. Mol
Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Cole KA, Attiyeh EF, Mosse YP, Laquaglia
MJ, Diskin SJ, Brodeur GM and Maris JM: A functional screen
identifies miR-34a as a candidate neuroblastoma tumor suppressor
gene. Mol Cancer Res. 6:735–742. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A
potential therapeutic target in human cancer. Cell Death Dis.
5:e13272014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Miao P, Sheng S, Sun X, Liu J and Huang G:
Lactate dehydrogenase A in cancer: A promising target for diagnosis
and therapy. IUBMB Life. 65:904–910. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Hennessey D, Martin LM, Atzberger A, Lynch
TH, Hollywood D and Marignol L: Exposure to hypoxia following
irradiation increases radioresistance in prostate cancer cells.
Urol Oncol. 31:1106–1116. 2013. View Article : Google Scholar
|
17
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warburg
effect in chemo-sensitivity: Targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar
|
18
|
Shimura T, Noma N, Sano Y, Ochiai Y,
Oikawa T, Fukumoto M and Kunugita N: AKT-mediated enhanced aerobic
glycolysis causes acquired radioresistance by human tumor cells.
Radiother Onco. 112:302–307. 2014. View Article : Google Scholar
|
19
|
Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ,
Zhao JH and Tang JH: MicroRNA-34a modulates chemosensitivity of
breast cancer cells to adriamycin by targeting Notch1. Arch Med
Res. 43:514–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Akao Y, Noguchi S, Iio A, Kojima K, Takagi
T and Naoe T: Dysregulation of microRNA-34a expression causes
drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer
Lett. 300:197–204. 2011. View Article : Google Scholar
|
21
|
Zhao J, Kelnar K and Bader AG: In-depth
analysis shows synergy between erlotinib and miR-34a. PLoS One.
9:e891052014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Kojima K, Fujita Y, Nozawa Y, Deguchi T
and Ito M: MiR-34a attenuates paclitaxel-resistance of
hormone-refractory prostate cancer PC3 cells through direct and
indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Martinez-Outschoorn UE, Lin Z, Ko YH,
Goldberg AF, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell
A, Sotgia F and Lisanti MP: Understanding the metabolic basis of
drug resistance: Therapeutic induction of the warburg effect kills
cancer cells. Cell Cycle. 10:2521–2528. 2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP,
Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, et al: Overcoming
trastuzumab resistance in breast cancer by targeting dysregulated
glucose metabolism. Cancer Res. 71:4585–4597. 2011. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zhong J, Rajaram N, Brizel DM, Frees AE,
Ramanujam N, Batinic-Haberle I and Dewhirst MW: Radiation induces
aerobic glycolysis through reactive oxygen species. Radiother
Oncol. 106:390–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Baskar R, Lee KA, Yeo R and Yeoh KW:
Cancer and radiation therapy: Current advances and future
directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Le A, Cooper CR, Gouw AM, Dinavahi R,
Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang
CV: Inhibition of lactate dehydrogenase A induces oxidative stress
and inhibits tumor progression. Proc Natl Acad Sci USA.
107:2037–2042. 2010. View Article : Google Scholar : PubMed/NCBI
|